title: Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model.
abstract: Initial clinical trials with daptomycin (2 mg/kg per day) were prematurely suspended because of unexplained treatment failures in patients with bacteremia who were treated with daptomycin, despite in vitro data indicating that the gram-positive cocci causing the infection were susceptible to daptomycin. One explanation for these clinical failures may relate to the relatively high degree of daptomycin protein binding (94%). To evaluate the impact of protein on daptomycin activity, a two-chamber in vitro pharmacodynamic model was used to study and compare the interaction between Staphylococcus aureus (clinical isolate) and either daptomycin or vancomycin, each in the presence and absence of physiologic human albumin concentrations. Low-dose (2 mg/kg) daptomycin, high-dose (6 mg/kg) daptomycin, and 10 mg of vancomycin per kg beta-phase elimination serum-concentration-versus-time curves were simulated by using this in vitro pharmacodynamic model. The bacterial kill rates by all three regimens were decreased in the presence of albumin (P less than 0.0002). The average times required for a 99% kill of the initial S. aureus inocula (approximately 5 x 10(7) CFU/ml) without albumin were 0.81 (low-dose daptomycin), 0.33 (high-dose daptomycin), and 6.18 (vancomycin) h. The average times required for a 99% kill of S. aureus with albumin were 7.66 (low-dose daptomycin), 0.95 (high-dose daptomycin), and 10.52 (vancomycin) h. These data demonstrate that, depending on the concentration of daptomycin, the presence of albumin can profoundly diminish the bactericidal activity of daptomycin.
authors.affiliation: College of Pharmacy, Washington State University, Spokane 99203.
authors.forename: M W
authors.initials: MW
authors.lastname: Garrison
authors.forename: K
authors.initials: K
authors.lastname: Vance-Bryan
authors.forename: T A
authors.initials: TA
authors.lastname: Larson
authors.forename: J P
authors.initials: JP
authors.lastname: Toscano
authors.forename: J C
authors.initials: JC
authors.lastname: Rotschafer
mesh_terms: D017576:Daptomycin; D004305:Dose-Response Relationship, Drug; D008954:Models, Biological; D010455:Peptides / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding; D012044:Regression Analysis; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D010455:Peptides; D014640:Vancomycin; D017576:Daptomycin